18 Oct 2017 07:00
Realm Therapeutics plc
("Realm Therapeutics", "Realm" or the "Company")
Block Listing Application
18 October 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, announces that an application has been made for the block admission, in aggregate, of 21,139,826 ordinary shares of 10p each in the Company (the "Block Admission Shares") in relation to certain outstanding, but not yet exercised warrants. The Block Admission Shares will be available to be issued as needed to satisfy the valid exercise of the following warrants:
- 20,898,448 Block Admission Shares in relation to a portion of the warrants issued in connection with the recent placing to raise £19.3 million ($26 million), as approved by shareholders on 9 October 2017 (the "Placing"); and
- 241,378 Block Admission Shares in relation to a portion of the warrants issued in December 2013 (and adjusted as a result of the Placing) in conjunction with the establishment of a credit facility with the Company's bank, the remainder of which are already subject to an existing block listing.
This block admission is further to the Company's existing block listing of ordinary shares of 10p each in connection with the Company's equity plans and in respect of the warrants issued in connection with the credit facility.
It is expected that the block admission will become effective on 23 October 2017. When issued, the Block Admission Shares will be credited as fully paid and will rank pari passu with the existing ordinary shares of the Company.
Enquiries:
Realm Therapeutics plc | +44 (0) 20 3727 1000 |
Alex Martin, Chief Executive Officer | |
Marella Thorell, Chief Financial Officer and Chief Operating Officer | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway / Mo Noonan | |
N+1 Singer (Nominated Adviser and Broker) | +44 (0) 20 7496 3000 |
Aubrey Powell / Lauren Kettle |
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.